Study Summary
This trial is testing whether two different ways of providing information to people considering genetic testing for cancer risk affects how likely they are to get the test.
Eligible Conditions
- Breast Cancer
- Ovarian Cancer
- Hormone-Refractory Prostate Cancer
- Pancreatic Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 9 Secondary · Reporting Duration: Up to 3 years
Immediately following intervention
Knowledge about genetics testing
Patient Satisfaction Survey following intervention
Result Disclosure Preference following intervention
Up to 3 years
Rate of patients who have germline genetic tests
after results have been received, four months post-intervention
Cascade testing in positives
Positive Results impact
after results have been received, two months post-intervention
Decisional Regret
Family communication of genetic test results
Interventional procedure
Psychological distress following intervention
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Group A: Standard genetic counseling
1 of 2
Group B: Educational video
1 of 2
Active Control
Experimental Treatment
220 Total Participants · 2 Treatment Groups
Primary Treatment: Educational Video · No Placebo Group · N/A
Group B: Educational video
Behavioral
Experimental Group · 1 Intervention: Educational Video · Intervention Types: BehavioralGroup A: Standard genetic counseling
Behavioral
ActiveComparator Group · 1 Intervention: Standard Genetic Counseling · Intervention Types: BehavioralTreatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Educational Video
2013
N/A
~660
Trial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 3 years
Who is running the clinical trial?
Dana-Farber Cancer InstituteLead Sponsor
1,016 Previous Clinical Trials
393,578 Total Patients Enrolled
134 Trials studying Breast Cancer
21,448 Patients Enrolled for Breast Cancer
Ambry GeneticsIndustry Sponsor
3 Previous Clinical Trials
485 Total Patients Enrolled
Huma Rana, MD5.05 ReviewsPrincipal Investigator - Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
5Patient Review
Dr. Rana is an excellent caretaker, especially for those with a genetic disposition for cancer. She is very knowledgeable and takes her time with each patient to ensure they feel comfortable and confident.
Eligibility Criteria
Age 18+ · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Potentially eligible participants will be identified from their medical records, or from their clinical visits if they are already patients at the enrolling Institution
is needed
No prior cancer genetic testing is necessary.
are the two essential ingredients for any research study
Cancers that originate in the breast, ovaries, pancreas, or metastatic prostate cancer.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments